The clinical relevance of this was supported by patient data of the TCGA cohort, which showed that S100A7 upregulation is more likely to be associated with increased miR-29b expression in ER+ breast cancer patients than ER− patients and vice versa. The gene discussed is ESR1; the disease is breast carcinoma.